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Acute lymphoblastic leukemia (ALL) is a heterogeneous group of lymphoid disorders characterized by monoclonal proliferation
and expansion of immature lymphoid cells in the bone marrow, blood, and other organs. It commonly presents with nonspeciﬁc
symptoms such as lethargy, easy bruising, and weight loss. In this article, we present the case of a 48-year-old male who presented
to the hospital with painless jaundice resulting from pancreatic inﬁltration, initially thought to be due to pancreatic or hep-
atobiliary malignancy. He was later diagnosed with ALL by lymph node biopsy and peripheral blood ﬂow cytometry immu-
nophenotyping and was transferred to a cancer treatment centre for unilateral bone marrow biopsy and further management. Our
case highlights the rare occurrence of pancreatic inﬁltration in ALL.
1. Introduction
Acute lymphoblastic leukemia is a malignant neoplasm
characterized by the proliferation of immature lymphoid
cells in the bone marrow, peripheral blood, or other organs
including the liver, pancreas, and kidneys. It is the com-
monest cancer among children and most frequent cause of
cancer mortality in children younger than 20 years [1, 2]. It
has an overall incidence of about 1.7 per 100,000 persons
with a bimodal distribution [3]. An early peak occurs at age
4–5 years with an incidence of 4–5/100,000 persons, fol-
lowed by a second gradual increase at about age 50 years with
incidence up to 2/100,000 persons [4]. -e 5-year overall
survival rate is about 90% in children compared to 30%
survival rate in older patients [4, 5]. Clinical features are
protean and include fatigue, dyspnea, bone pain, easy
bruising, and dizziness including B symptoms such as fever,
weight loss, and night sweats. Physical ﬁndings commonly
include pallor, ecchymosis, petechiae, lymphadenopathy,
and splenomegaly. So far, only few cases of obstructive
jaundice resulting from leukemic inﬁltration of the pancreas
in acute lymphoblastic leukemia have been reported in
literature [6, 7].
2. Case History
A 48-year-old man with no signiﬁcant past medical history
presents to the emergency department with 1 week history of
worsening jaundice associated with passage of dark coloured
urine and pale stools. He denied abdominal pain, fever,
chills, rigors, or night sweats. He had no skin rashes, pru-
ritus, or easy bruising. He also reported no anorexia or
unintentional weight loss. He was a nonsmoker and a
nonalcoholic with no family history of malignancy. Vital
signs were normal and physical examination was positive
only for generalized icterus. He had no peripheral lymph-
adenopathy. Complete blood count revealed pancytopenia
with white blood cell count of 3200/ml (normal 4800–10800/
ml), hemoglobin of 13.8 g/dL (normal 14.0–17.5 g/dL), and
platelet count of 71000/ml (normal 130000–400000/ml).
Basic metabolic panel, including renal function test, was
normal. Liver function test revealed alkaline phosphatase of
147U/L (normal 34–104U/L), aspartate transaminase of
65U/L (normal 13–39U/L), alanine transaminase of 190U/
L (normal 7–52U/L), total bilirubin of 7.2mg/dL (normal
0.3–1.0mg/dL), and direct bilirubin of 4.3mg/dL (normal<0.2mg/dL). Abdominal ultrasound scan revealed 4.5 cm
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hypoechoic mass adjacent to the pancreatic tail with mild
splenomegaly. It also reported mild dilatation of the com-
mon bile duct without sonographic evidence of acute
cholecystitis. Computed tomography (CT) scan of the ab-
domen and pelvis with contrast (Figure 1) revealed 36 ×
33mm mass-like thickening of the pancreatic body with a
nodular mass contiguous with the pancreatic head and
multiple renal masses. CT scans of the head and chest, done
to exclude presence of other primary source or metastatic
disease, were normal.
Based on the history of painless obstructive jaundice and
the imaging ﬁndings above, our initial suspicion was pan-
creatic or bile duct malignancy. IgG4-related disease was
also considered in the diﬀerential diagnosis. Autoimmune
diseases may also present as painless jaundice but less
common in males with no family history of autoimmune
disease. Interestingly, carcinoembryonic antigen (CEA) was
1.4 ng/mL (normal <3 ng/mL) and CA 19–9 was 28U/mL
(normal <37U/mL). IgG4 level was 38mg/dL (normal 1–
123mg/dL).
He was planned for diagnostic esophagogastroduodeno-
scopy, endoscopic ultrasound scan, and ﬁne needle aspiration
which revealed multiple enlarged hypoechoic homogenous
malignant appearing lymph nodes within the peripancreatic,
perihepatic, and periportal regions. Biopsy conﬁrmed pre-
cursor B acute lymphoblastic lymphoma. Peripheral blood
ﬂow cytometry also revealed mixture of cells with lymphoid
predominance. A monoclonal population of blasts coex-
pressing CD10/CD19/CD20/CD22/CD38/HLA-DR/CD79a
and TdT was noted. CD34 expression was not seen. Cyto-
genetic studies were negative for deletion of CDKN2A (p16),
rearrangement of KMT2A (MLL) and TCRA/D, and
translocation of ETV6/RUNX1 and BCR/ABL1. -is phe-
notypic expression was consistent with B-cell lymphoblastic
lymphoma, and a diagnosis of acute lymphoblastic lym-
phoma (ALL) was made. He was promptly transferred to the
regional cancer centre for further evaluation and treatment.
At the cancer centre, his liver enzymes worsened and he
underwent endoscopic retrograde cholangiopancreatog-
raphy (ERCP) which revealed a stricture at the common bile
duct (CBD) and underwent sphincterotomy and stent de-
ployment and gradual resolution of deranged liver enzymes.
He consented to enrolment in a clinical trial and was com-
menced on daunorubicin, vincristine, methotrexate, cyclo-
phosphamide, rituximab, pegaspargase, and intrathecal
cytarabine. He was discharged home in the stable condition
after 2 weeks and planned for weekly intrathecal chemo-
therapy and follow-up with the oncologist.
3. Discussion
Our patient was diagnosed with acute lymphoblastic leu-
kemia (ALL). Typical symptoms include the B symptoms
such as fever, unintentional weight loss, and night sweat.
Recurrent infections, easy bruisability, bleeding, fatigue, and
bone pain reﬂect the progressive bone marrow failure and
expansion of the marrow by immature blast cells [9, 13].
Extramedullary involvement in ALL is not unusual with the
leukemic cells commonly inﬁltrating the central nervous
system, testes, lymph nodes, and spleen [8]. It is believed that
the overexpression of CXCR4, a chemokine receptor, on
abnormal leukemic lymphoblasts is associated with extra-
medullary inﬁltration. -ese receptors bind to the chemo-
kine stromal-cell-derived factor-1 (SDF-1), a potent
molecule for chemotaxis of lymphocytes found in the bone
marrow and other tissues [14]. Rare cases of pancreatic and
hepatic involvement with extrahepatic and intrahepatic bile
duct obstruction causing cholestatic jaundice as an initial
presentation have also been reported in adult ALL [6, 7].
Adult ALL is a less common haematological malignancy
making up about 20% of acute leukemias in adult, with a
poor survival rate of 30–40% compared to the higher sur-
vival rate of about 90% in paediatric ALL [8]. -ree subtypes
exist based on the morphology and cytogenetic proﬁle as
described by the World Health Organisation (WHO)-B
lymphoblastic, T lymphoblastic, and the Burkitt leukemia.
-e B-cell lymphoblastic leukemia accounts for about 75%
of adult ALL [9]. Earlier classiﬁcation system by French
American British (FAB) based purely on morphology of the
leukemic cells is now considered obsolete. -e exact cause is
unknown, but multiple genetic conditions and environ-
mental exposures are known to increase the risk of de-
veloping ALL. Incidence is higher in patients with Down
syndrome with a 20-fold increase in risk, Fanconi anemia,
Bloom syndrome, and ataxia telangiectasia as well as en-
vironmental exposure to benzene products, ionizing radi-
ations, and viruses including Epstein–Barr virus and human
immunodeﬁciency virus [9, 10]. Common cytogenetic ab-
normalities in the form of chromosomal translocation seen
in ALL include t(9; 22), t(4; 11), and t(12; 21). Adult ALL is
associated with t(9; 22) (q34; q11) (Philadelphia chromo-
some) with the BCR-ABL1 fusion in 15–30% representing
the most frequent molecular abnormality [11]. -is is in
contrast to paediatric ALL where t (12; 21) (p13, q22) is the
most common chromosomal translocation and carries a
favourable prognosis [12]. Presence of Philadelphia chro-
mosome is believed to be a poor prognostic feature and is
seen more in adult ALL [11].
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Figure 1: Computed tomography scan of the abdomen showing
33.2mm mass in the pancreatic body. Multiple bilateral renal
masses can also be appreciated.
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Our patient had both pancreatic and bilateral renal
involvements, and his obstructive jaundice was believed to
be secondary to the pancreatic masses as evidenced by the
mildly dilated CBD without any obvious hepatic or gall
bladder pathologies. Involvement of the pancreas in ALL is
very rare and even more uncommon is the concurrent renal
involvement [15]. Only few publications exist for adult ALL
presenting primarily with obstructive jaundice secondary to
pancreatic inﬁltration by leukemic cells. Daniel et al. re-
ported the ﬁrst case of obstructive jaundice from pancreatic
masses compressing the common bile duct (CBD) in adult
ALL [7]. Another rare case of leukemic inﬁltration of hepatic
sinusoids resulting in cholestasis without pancreatic in-
volvement was described by Siddique et al. [6].
-e diﬀerential diagnoses of jaundice are broad, some-
times presenting a diagnostic dilemma as seen in our case
where the initial suspicion was hepatobiliary or pancreatic
malignancy. It is therefore prudent for clinicians to consider
this possibility during initial diagnostic workup of patients
presenting with obstructive jaundice to forestall unnecessary
invasive investigations. Obstructive jaundice in ALL may
also pose a challenge during initiation of treatment because
most chemotherapeutic agents are metabolized by the liver;
however, if liver dysfunction is directly attributable to ALL,
judicious use of cytoreductive treatment with selected agents
may lead to improved liver function and thus facilitate safer
administration of deﬁnitive induction therapy [16].
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